ALTOONA, Pa. — After UnitedHealthcare’s CEO was gunned down on a New York sidewalk, police searched for the masked gunman with dogs, drones and scuba divers. Officers used the city's muscular surveillance system. Investigators analyzed DNA samples, fingerprints and internet addresses. Police went door-to-door looking for witnesses. When an arrest came five days later, those sprawling investigative efforts shared credit with an alert civilian's instincts. A Pennsylvania McDonald's customer noticed another patron who resembled the man in the oblique security-camera photos that New York police had publicized. Deputy Commissioner of Operations Kaz Daughtry speaks during a press conference regarding the arrest of suspect Luigi Mangione, Monday, Dec. 9, 2024, in Hollidaysburg, Pa., in the fatal shooting of UnitedHealthcare CEO Brian Thompson. (AP Photo/Ted Shaffrey) Luigi Nicholas Mangione, a 26-year-old Ivy League graduate from a prominent Maryland real estate family, was arrested Monday in the killing of Brian Thompson, who headed one of the United States’ largest medical insurance companies. He remained jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. By late evening, prosecutors in Manhattan had added a charge of murder, according to an online court docket. He's expected to be extradited to New York eventually. It’s unclear whether Mangione has an attorney who can comment on the allegations. Asked at Monday's arraignment whether he needed a public defender, Mangione asked whether he could “answer that at a future date.” Mangione was arrested in Altoona, Pennsylvania, after the McDonald's customer recognized him and notified an employee, authorities said. Police in Altoona, about 233 miles (375 kilometers) west of New York City, were soon summoned. This booking photo released Monday, Dec. 9, 2024, by the Pennsylvania Department of Corrections shows Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson. (Pennsylvania Department of Corrections via AP) They arrived to find Mangione sitting at a table in the back of the restaurant, wearing a blue medical mask and looking at a laptop, according to a Pennsylvania police criminal complaint. He initially gave them a fake ID, but when an officer asked Mangione whether he’d been to New York recently, he “became quiet and started to shake,” the complaint says. When he pulled his mask down at officers' request, “we knew that was our guy,” rookie Officer Tyler Frye said at a news conference in Hollidaysburg. New York Police Commissioner Jessica Tisch said at a Manhattan news conference that Mangione was carrying a gun like the one used to kill Thompson and the same fake ID the shooter had used to check into a New York hostel, along with a passport and other fraudulent IDs. NYPD Chief of Detectives Joseph Kenny said Mangione also had a three-page, handwritten document that shows “some ill will toward corporate America." An NYPD police officer and K-9 dog search around a lake in Central Park, Monday, Dec. 9, 2024, in New York. (AP Photo/Yuki Iwamura) A law enforcement official who wasn’t authorized to discuss the investigation publicly and spoke with The Associated Press on condition of anonymity said the document included a line in which Mangione claimed to have acted alone. “To the Feds, I’ll keep this short, because I do respect what you do for our country. To save you a lengthy investigation, I state plainly that I wasn’t working with anyone,” the document said, according to the official. It also had a line that said, “I do apologize for any strife or traumas but it had to be done. Frankly, these parasites simply had it coming.” Pennsylvania prosecutor Peter Weeks said in court that Mangione was found with a passport and $10,000 in cash — $2,000 of it in foreign currency. Mangione disputed the amount. Thompson, 50, was killed last Wednesday as he walked alone to a midtown Manhattan hotel for an investor conference. Police quickly came to see the shooting as a targeted attack by a gunman who appeared to wait for Thompson, came up behind him and fired a 9 mm pistol. Investigators have said “delay,” “deny” and “depose” were written on ammunition found near Thompson’s body. The words mimic a phrase used to criticize the insurance industry. A poster issued by the Federal Bureau of Investigation shows a wanted unknown suspect. (FBI via AP) From surveillance video, New York investigators gathered that the shooter fled by bike into Central Park, emerged, then took a taxi to a northern Manhattan bus terminal. Once in Pennsylvania, he went from Philadelphia to Pittsburgh, “trying to stay low-profile” by avoiding cameras, Pennsylvania State Police Lt. Col. George Bivens said. A grandson of a wealthy, self-made real estate developer and philanthropist, Mangione is a cousin of a current Maryland state legislator. Mangione was valedictorian at his elite Baltimore prep school, where his 2016 graduation speech lauded his classmates’ “incredible courage to explore the unknown and try new things.” He went on to earn undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a spokesperson said. “Our family is shocked and devastated by Luigi’s arrest,” Mangione’s family said in a statement posted on social media late Monday by his cousin, Maryland lawmaker Nino Mangione. “We offer our prayers to the family of Brian Thompson and we ask people to pray for all involved.” Luigi Nicholas Mangione worked for a time for the car-buying website TrueCar and left in 2023, CEO Jantoon Reigersman said by email. From January to June 2022, Mangione lived at Surfbreak, a “co-living” space at the edge of Honolulu tourist mecca Waikiki. Like other residents of the shared penthouse catering to remote workers, Mangione underwent a background check, said Josiah Ryan, a spokesperson for owner and founder R.J. Martin. “Luigi was just widely considered to be a great guy. There were no complaints,” Ryan said. "There was no sign that might point to these alleged crimes they’re saying he committed.” At Surfbreak, Martin learned Mangione had severe back pain from childhood that interfered with many aspects of his life, from surfing to romance, Ryan said. “He went surfing with R.J. once but it didn’t work out because of his back," Ryan said, but noted that Mangione and Martin often went together to a rock-climbing gym. NYPD officers in diving suits search a lake in Central Park, Monday, Dec. 9, 2024, in New York. (AP Photo/Yuki Iwamura) Mangione left Surfbreak to get surgery on the mainland, Ryan said, then later returned to Honolulu and rented an apartment. Martin stopped hearing from Mangione six months to a year ago. Although the gunman obscured his face during the shooting, he left a trail of evidence in New York, including a backpack he ditched in Central Park, a cellphone found in a pedestrian plaza, a water bottle and a protein bar wrapper. In the days after the shooting, the NYPD collected hundreds of hours of surveillance video and released multiple clips and still images in hopes of enlisting the public’s eyes to help find a suspect. “This combination of old-school detective work and new-age technology is what led to this result today,” Tisch said at the New York news conference. ___ Scolforo reported from Altoona and Hollidaysburg, Pennsylvania. Contributing were Associated Press writers Cedar Attanasio and Jennifer Peltz in New York; Michael Rubinkam and Maryclaire Dale in Pennsylvania; Lea Skene in Baltimore and Jennifer Sinco Kelleher in Honolulu. Get local news delivered to your inbox!

Alijah Johnson is a man of many talents: firefighter, paramedic, social influencer, model, and filmmaker. He spoke about his latest endeavors. Margaret Mead once said: “Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.” This quote applies to Alijah Johnson. From its humble beginnings, The Australian Firefighters Calendar was established in 1993 to support the Children’s Hospital Foundation, providing funds for research into childhood burns. Now in its 31st year, The Australian Firefighters Calendar has raised over $3.45 million for various charities. “Any charity is important, especially to help out those that are vulnerable and less fortunate,” Johnson said. “It’s a very unreal feeling to be in this calendar.” “Animals, in particular, can’t necessarily help themselves so we need to step in and do our job,” he said. “It is very rewarding to help out other people and to be generous in that way. The calendar definitely helps out many good causes.” On being a part of the 2025 Australian Firefighters Calendar, Johnson exclaimed, “It was great! It was something that I didn’t see coming. I never thought about going to Australia before but being flown there was definitely a wonderful opportunity and experience. I loved it!” “It was such a blessing to be in Australia for the Australian Firefighters Calendar,” he acknowledged. “I thought it was very professional and organized.” “I do modeling on the side, so the calendar allowed me to do both of my passions: modeling and firefighting,” he added. Johnson was able to break the glass ceiling. He made history as the first African American firefighter that was featured in the 2025 Australian Firefighters Calendar. “That was really surprising when they told me about that fact... to be the first in 32 years is such a great honor,” he said. “This is the second year that they flew American firefighters out to be a part of the Australian Firefighters Calendar, so it was great to represent America in that aspect,” Johnson noted. This year, the Australian Firefighters Calendar is supporting American citizens and animals affected by Hurricanes Helene and Milton in Florida. “It is really great to see how Australia supports America whenever we are in tragedy, and the same is true vice versa, when America would help Australia during the wildfires. It is very cool to see these countries supporting each other,” Johnson said. Through their partnership with Greater Good Charities, they are donating funds to provide immediate relief and aid to impacted communities. This collaboration aims to deliver essential resources, such as food, shelter, and medical assistance, to those in need, helping families rebuild their lives after the devastation of the hurricane. Johnson revealed that he has been a firefighter for seven years. “I started when I was 21 years old,” he said. “I was young when I started, and my colleagues at work bring up the fact that I am in the calendar every day.” “I appreciate the praise and the support and love that comes with being on the Australian Firefighters Calendar,” he said, effusively. Johnson opened up about his “Circles” short film, which has been winning awards in the film festival circuit. “I has won numerous awards around the world in different countries,” he admitted. “This short helped me grow as a person so much, and it helped me learn so much about myself while making it,” he said. “It is insane to see how people connect with something that was so personal to me. During that time, I was going through a breakup and I needed something to be productive with to get my creative juices flowing. It was such a therapeutic experience for me,” he elaborated. “This project allowed me to turn tragedy into a masterpiece. I was able to transmit that energy into something positive, and it is so great and fulfilling that it is connecting with people on a global scale so I feel very blessed and fulfilled,” he expressed. On the title of the current chapter of his life, he said, “Swimming.” “I just keep swimming,” he said. “Also, it is important not to give up. It is about persevering and being persistent.” His superpower of choice would be superstrength and wisdom. Regarding his definition of success, he said, “Success is something very intangible, something priceless, and it is very unique to me. Success is a happy family with a nice house rather than be a billionaire. To me, that’s priceless.” For fans and readers, Johnson remarked about the 2025 Australian Firefighters Calendar, “This is all for a good cause. Donating to these charities will be great. There are a lot of physically fit firefighters in there, and they can be an inspiration to you all.” To learn more about Alijah Johnson, follow him on Instagram . For more information on the 2025 Australian Firefighters Calendar, check out its official homepage . Markos Papadatos is Digital Journal's Editor-at-Large for Music News.Papadatos is a Greek-American journalist and educator that has authored over 22,000 original articles over the past 18 years. He has interviewed some of the biggest names in music, entertainment, lifestyle, magic, and sports. He is a 16-time "Best of Long Island" winner, where for three consecutive years (2020, 2021, and 2022), he was honored as the "Best Long Island Personality" in Arts & Entertainment, an honor that has gone to Billy Joel six times.Letter: Stop the attacks

Philadelphia star quarterback Jalen Hurts remains in concussion protocol and has been ruled for Sunday's game against the visiting Dallas Cowboys, with the Eagles expected to start Kenny Pickett. Hurts missed practice all week, and head coach Nick Sirianni confirmed before Friday's session that Hurts remains in the concussion protocol, adding, "It's going to be tough for him to make it this week." Hurts and Pickett (ribs) were both injured during last weekend's 36-33 loss to the Washington Commanders, but Pickett was a full participant in Thursday's practice and was limited on Friday. The Eagles also have Tanner McKee as the emergency third quarterback and signed Ian Book to the practice squad this week. Pickett, who grew up as an Eagles fan in Ocean Township, N.J., will have a chance to help Philadelphia (12-3) clinch the NFC East title in his first start for the franchise. "I'm very excited. It's a big opportunity," he told reporters Thursday. "I've been working hard to stay ready and I felt like I was in a good position last game with my preparation and now having a week to practice, I'll feel even better going into the stadium. So, I'm excited. I just want to get the win." Pickett relieved Hurts in the first quarter against Washington and completed 14 of 24 passes for 143 yards with one touchdown and one interception. Prior to that, he had appeared in three games in mop-up duty. "He's done a great job," Eagles wide receiver A.J. Brown said on Friday. "He did a great job last week. I know he had a few hiccups, but overall he's doing a great job. It's not his first rodeo. We have a lot of confidence in him, I do, and I'm excited. "(He's) poised, confident. He comes in, he's commanding the huddle and that's what you want to see." Pickett, 26, compiled a 14-10 record as the starter for the Steelers from 2022-23 after being drafted by Pittsburgh in the first round (20th overall) in 2022. After the Steelers acquired Russell Wilson in March, Pickett was traded along with a 2024 fourth-round pick to the Eagles in exchange for a 2024 third-round pick and two 2025 seventh-rounders. Pickett has completed 62.3 percent of his pass attempts for 4,622 yards with 14 touchdowns and 14 interceptions in 29 career games. He has rushed for 303 yards and four scores. Hurts, 26, has completed 68.7 percent of his passes this season for 2,903 yards with 18 TDs and five picks in 15 starts. He has rushed for 630 yards and is tied for the NFL lead with 14 rushing touchdowns. --Field Level MediaYou may know of him from Dragon’s Den — or Shark Tank- or Fox News. Now, Kevin O’Leary is promising to bring a $70 billion AI data centre to northwestern Alberta. “$70 billion is probably the largest real estate project ever proposed in Canada. It’s certainly the largest data centre proposed in globally right now,” said O’Leary. O’Leary, who calls himself Mr. Wonderful, announced Wonder Valley on Monday. It’s a 7,000 acre data centre park — to be built about 42 kilometres south of Grande Prairie in the MD of Greenview. Why there? Well, in an interview with CityNews he said it’s because of low taxes, a talented work force and an abundance of natural gas for power generation. “We could probably be the world’s leaders in the development of AI technology and AI data centres because of one thing: our power. No one can compete with the power we have and that’s exactly what AI needs,” said O’Leary. Local officials say highway 40 is already being upgraded to handle the boom. Most of the workers, 3,000 to 5,000 during construction and about 1,000 ongoing are expected to commute south from Grande Prairie. “What you’re doing is just taking a really consistent economy and you’re just giving it a jolt. And that jolt is just diversification,” said Kyle Reiling, MD of Greenview Executive Director. O’Leary says he’s already optioned the land, the power turbines are expected to be up and running in 24 months and the data centres will be built in phases. He says he’s been working with the premier’s office on this, adding a likely change to a conservative government in Ottawa is giving him and other investors a renewed confidence in doing business in Canada. “This will provide thousands of jobs during the construction phase, over the next 5 to 7 years. And many of those will be high-paying jobs, luckily Alberta has a very trained number of people who can do this,” said O’Leary. Last week, the Alberta government announced a plan to attract $100 billion in AI data centre investment. O’Leary agrees that’s possible and his project could go a long way to realizing that.

SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.

Syrian government services come to a 'complete halt' as state workers stay home